Ophthotech has completed patient enrolment in its Phase llb clinical trial of Zimura (avacincaptad pegol) to treat patients with geographic atrophy secondary to dry age-related macular degeneration (AMD).

A total of 286 patients have been enrolled for the randomised, double-masked, sham controlled multi-centre clinical trial.

The trial aims to evaluate the safety and efficacy of various doses of Zimura over a period of 12 months, followed by treatment and monitoring of patients for 18 months.

Ophthotech chief medical officer Kourous Rezaei said: “Recent clinical data together with the pre-clinical scientific evidence implicating complement in various retinal diseases further invigorates our enthusiasm for the therapeutic potential of Zimura.

“We look forward to initial top-line data from this clinical trial, which is expected to be available during the fourth quarter of 2019.”

“We look forward to initial top-line data from this clinical trial, which is expected to be available during the fourth quarter of 2019.”

Zimura is developed to target and inhibit the complement protein C5.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The solution is also being studied in combination with anti-vascular endothelial growth factor (anti-VEGF) agent Lucentis (ranibizumab) at 0.5mg in treatment-naïve wet AMD patients as part of an open-label Phase lla trial.

The randomised, dose-ranging, open-label, uncontrolled, multi-centre trial has included 64 patients.

The trial is expected to provide initial top-line results by the end of this year.

Based on the results, Ophthotech will decide whether to proceed to a randomised, sham-controlled clinical study of Zimura combination therapy with anti-VEGF in wet AMD.

In addition, Zimura is being investigated in a Phase llb clinical trial in patients with autosomal recessive Stargardt disease (STGD1).